Announced Sat, 30 May · 15:55 IST

Audited Financial Results for March 31, 2026

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+3.1%1-day move

₹442.00

prior close

₹454.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.1+1.1+1.3+1.3+3.1+2.5+0.2+0.5-1.1+0.4-2.1-15.8——

Up moveDown movePending

AI summary

Titan Biotech reported strong audited results for FY2026 with standalone total income of ₹2,116.01 Crores, up 31.9% from ₹1,603.63 Crores in FY2025. Profit after tax grew 50.2% to ₹274.47 Crores from ₹182.71 Crores. EPS improved to ₹6.64 per share (post stock split from ₹10 to ₹2 face value). The board recommended dividend of ₹0.50 per equity share. Net cash from operating activities remained positive at ₹304.08 Lakhs. Consolidated PAT including associates was ₹299.85 Lakhs. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financials.

Likely market impact

The company delivered robust double-digit growth in both revenue and profitability with strong PAT growth of over 50%. Positive operating cash flows and a clean audit opinion support financial stability. The stock split may improve liquidity and accessibility for smaller investors.